Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · EMCURE

EMCURE

HealthcarePharmaceuticals & Biotechnology₹44310 cr market cap
₹2344.70 ▲ +0.42% today As of 19 Nov 2026
52-week low ₹1337.4052-week high ₹2361.70

-1.1% from the 52-week high · +74.6% above the low

Emcure Pharmaceuticals Ltd develops, manufactures, and markets pharmaceutical products across multiple therapeutic segments. The company emphasizes quality, regulatory compliance, and global market outreach in both branded and generic medicines.

The short version. EMCURE reported revenue of ₹2,820 crore for Sep 2026, up 24.2% from a year earlier. Net profit was ₹326 crore (up 34.2% year on year). Return on equity was 18.7% in Mar 2026. Promoter holding was 77.82% in Sep 2026, down 0.12 points over 8 quarters.

1 · The price

How has the stock traded?

EMCURE trades 1.1% below its 52-week high and 74.6% above its 52-week low.

Change over period: —

1M+32.2%
3M+23.5%
6M+34.6%
1Y+71.6%

2 · The business

Is it growing?

Sales, year on year+24.2%

Sep 2026 revenue of ₹2,820 cr.

Profit, year on year+34.2%

Sep 2026 net profit of ₹326 cr.

Net margin11.5%

0.8 pts higher than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue28202580247023632270210121161963
Net profit326294243231243207189154
Net margin %11.511.49.99.810.79.98.97.8
EPS (₹)17.1615.512.8412.1612.8410.929.978.11

Annual

FY2026FY2025
Revenue92047896
Net profit924681
Net margin %10.08.6
EPS (₹)48.7635.96

3 · The quality

How well does it turn capital into profit?

Return on equity was 18.7% in Mar 2026; debt to equity is 0.24.

Profitability · 2 years

Returns and margins

Mar 2026Mar 2025
Return on equity %18.715.3
Return on capital %25.120.6
EBITDA margin %20.019.2
Net margin %10.08.6

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
Debt to equity0.24
Interest cover10.0x
Current ratio1.46
P/E ratio49.0

4 · The owners

Who holds it, and are they adding?

Promoter holding77.82%

Down 0.12 pts over 8 quarters.

Foreign institutions4.94%

Up 1.89 pts over 8 quarters.

Domestic institutions8.49%

Up 4.62 pts over 8 quarters.

Mutual fund schemes76

+14 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter77.9477.9277.9177.8977.8877.8777.8377.82-0.12
FII3.053.072.863.293.593.354.884.94+1.89
DII3.873.442.844.376.16.18.468.49+4.62
Public15.1415.5716.3914.4612.4412.688.838.75-6.39

Mutual fund holdings · Oct 2026

76 schemes hold this stock

62 the month before.

  • Bajaj Finserv Healthcare Fund3.76% of NAV
  • ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND3.06% of NAV
  • Baroda BNP Paribas Small Cap Fund2.63% of NAV
  • ADITYA BIRLA SUN LIFE ELSS TAX SAVER FUND1.89% of NAV
  • the Quantum Flexi Cap Fund1.78% of NAV
  • Kotak Healthcare Fund1.63% of NAV
  • Baroda BNP Paribas Health and Wellness Fund1.57% of NAV
  • The Wealth Company Large & Mid Cap Fund1.4% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for EMCURE are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about EMCURE

What is the EMCURE share price?

EMCURE (EMCURE) last closed at ₹2,344.70, up 0.42% on the day. Its 52-week range is ₹1,337.40 to ₹2,361.70.

What is the market cap of EMCURE?

EMCURE has a market capitalisation of about ₹44,310 crore. Its price-to-earnings ratio is 49.0.

How are EMCURE's latest results?

EMCURE reported revenue of ₹2,820 crore for Sep 2026, up 24.2% from a year earlier. Net profit was ₹326 crore (up 34.2% year on year). Return on equity was 18.7% in Mar 2026. Promoter holding was 77.82% in Sep 2026, down 0.12 points over 8 quarters.

Who owns EMCURE?

As of Sep 2026, shareholding was: Promoter 77.82%, FII 4.94%, DII 8.49%, Public 8.75%.

How many mutual funds hold EMCURE?

76 mutual fund schemes held EMCURE in October 2026. That compares with 62 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 14 Aug 2025 · Final Dividend - Rs. 3

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.